25 Results for "

CK2α

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "CK2α" in MCE Product Catalog:

59
59 Publications Verification
Cat. No.: HY-50855
CAS No.: 1009820-21-6
Synonyms: CX-4945
Target:  

Casein Kinase Autophagy

Research Areas:  

Cancer

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
59
59 Publications Verification
Cat. No.: HY-50855B
CAS No.: 1309357-15-0
Synonyms: CX-4945 sodium salt
Target:  

Casein Kinase Autophagy

Research Areas:  

Cancer

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-139004
CAS No.: 2470424-39-4
Purity:  99.67%
Target:  

Casein Kinase

Research Areas:  

Neurological Disease

SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases [2].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108606
CAS No.: 942289-87-4
Purity:  99.62%
Target:  

PI3K Casein Kinase

Research Areas:  

Cancer

PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid kinase assay, respectively .
loading...
    loading...
Cat. No.: HY-148318
CAS No.: 443747-52-2
Purity:  98.34%
Target:  

Casein Kinase

Research Areas:  

Cancer

CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies .
loading...
    loading...
Cat. No.: HY-156816
CAS No.: 1585246-23-6
Purity:  99.73%
Synonyms: 108600
Research Areas:  

Cancer

ON 108600 (108600) is a CK2 (CK2α1: IC50 = 50 nM; CK2α2 = 5 nM), TNIK (IC50 = 5 nM) and DYRK (DYRK1A: IC50 = 16 nM; DYRK1B = 7 nM; DYRK2: = 28 nM). ON 108600 suppresses the growth of CD44high/CD24low breast cancer stem cell (BCSC) populations, induces G2/M arrest and apoptosis in triple negative breast cancer (TNBC) cells, and inhibits tubulin polymerization. ON 108600 can be used for the study of chemotherapy-resistant and metastatic TNBC [2].
loading...
    loading...
Cat. No.: HY-176508
CAS No.: 2757728-47-3
Target:  

Casein Kinase

Research Areas:  

Cancer

KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
loading...
    loading...
Cat. No.: HY-178980
CAS No.: 2830619-57-1
Target:  

Casein Kinase

Research Areas:  

Cancer

APL-5125 (Compound 61f) is a potent, selective and orally active ATP-competitive CK2α inhibitor with an IC50 of 0.348 nM and a Ki of 0.095 nM. APL-5125 binds to CK2α in a bivalent manner, simultaneously interacting with the ATP-binding site and the αD pocket. APL-5125 exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
loading...
    loading...
Cat. No.: HY-50855R
CAS No.: 1009820-21-6
Synonyms: CX-4945 (Standard)
Research Areas:  

Cancer

Silmitasertib (Standard) is the analytical standard of Silmitasertib. This product is intended for research and analytical applications. Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
Cat. No.: HY-156470
CAS No.: 3009081-73-3
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .
loading...
    loading...
Cat. No.: HY-123853
CAS No.: 2101206-81-7
Target:  

Casein Kinase

Research Areas:  

Cancer

CAM4066 is a potent CK2α inhibitor, with an IC50 value of 300 nM. CAM4066 exhibits high selectivity, with IC50 values of 22.35, 43.55, and > 50 μM for HIPK3, DAPK3, and CLK2, respectively. CAM4066 shows no cell activity. CAM4066 can be used for the development of highly potent CK2 inhibitors .
loading...
    loading...
Cat. No.: HY-50855BR
CAS No.: 1309357-15-0
Synonyms: CX-4945 sodium salt (Standard)
Research Areas:  

Cancer

Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt). This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
Cat. No.: HY-151382
CAS No.: 2969205-85-2
Target:  

Casein Kinase

Research Areas:  

Cancer

CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM), with IC50 values of 1.51 μM (CK2α) and 7.64 μM (CK2α’). CK2-IN-3 can be used in the research of cancers .
loading...
    loading...
Cat. No.: HY-158370
CAS No.: 2938991-22-9
Target:  

Casein Kinase

Research Areas:  

Cancer

CK2-IN-11 (32) is an allosteric CK2 inhibitor, with high selectivity for CK2 with IC50 values of 19.3 nM and 15.6 nM for the CK2α2β2 and the CK2α′2β2 isoforms, respectively .
loading...
    loading...
Cat. No.: HY-146138
CAS No.: 2492382-37-1
EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis .
loading...
    loading...
Cat. No.: HY-171744
CAS No.: 1333382-32-3
Target:  

Casein Kinase

Research Areas:  

Cancer

CX-5279 is an efficient and selective CK2 inhibitor with IC50 values for nCK2 and CK2α of 2.73 and 0.91 nM, respectively. CX-5279 is sensitive to mutations at Val66, Ile174, and V66I174AA, with IC50 values of 13.8, 12.5, and 23.35 nM, respectively. CX-5279's inhibitory activity against PIM1 is very weak, with a IC50 value of 8.52 μM. CX-5279 exhibits anti-proliferative activity in various cancer cell lines. CX-5279 can be used for research on cancers such as pancreatic cancer and leukemia .
loading...
    loading...
Cat. No.: HY-184458
CAS No.: 1009821-64-0
Target:  

Casein Kinase

Research Areas:  

Cancer

CX-5279 free acid is an efficient and selective CK2 inhibitor with IC50 values for nCK2 and CK2α of 2.73 and 0.91 nM, respectively. CX-5279 free acid is sensitive to mutations at Val66, Ile174, and V66I174AA, with IC50 values of 13.8, 12.5, and 23.35 nM, respectively. CX-5279 free acid's inhibitory activity against PIM1 is very weak, with a IC50 value of 8.52 μM. CX-5279 free acid exhibits anti-proliferative activity in various cancer cell lines. CX-5279 free acid can be used for research on cancers such as pancreatic cancer and leukemia .
loading...
    loading...
Cat. No.: HY-108606R
CAS No.: 942289-87-4
Research Areas:  

Cancer

PI-828 (Standard) is the analytical standard of PI-828 (HY-108606). This product is intended for research and analytical applications. PI-828 is a dual PI3K and casein Kinase 2 (CK2) inhibitor with IC50s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2 in lipid Kinase assay, respectively .
loading...
    loading...
Cat. No.: HY-181442
CAS No.: 313226-24-3
CK2-TN03 is an ATP-competitive casein kinase 2 (CK2) inhibitor, with an IC50 of 165 nM and a Ki of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1. CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin, leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma .
loading...
    loading...
Cat. No.: HY-183627
Target:  

PI5P4K

Research Areas:  

Cancer

066ATZ is a PIP4K2A/2B inhibitor with human PIP4K2A Ki 100 nM and PIP4K2B Ki 800 nM. 066ATZ binds to ATP-binding sites of PIP4K2A and PIP4K2B to block lipid kinase activity. 066ATZ can be used for the research of non-small cell lung cancer .
loading...
    loading...